DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|gX | LOCK|!% | LOCK|d<#$HFv |
DSM-Firmenich Earnings: Sales Growth Ahead of Peers Reinforces Outlook; Shares Fairly Valued
DSM-Firmenich reported organic sales growth accelerating to 6% in the second quarter, outpacing its own full-year guidance and Vara-compiled consensus. EBITDA margin also saw a slight increase. Shares rose about 13% on July 30.
